As the biopharmaceutical sector traverses the complex terrain of 2025, it encounters a multitude of challenges shaped by financial constraints, regulatory shifts, and evolving geopolitical dynamics. The industry is marked by notable changes detailed in Ernst & Young LLP's (EY) annual Biotech Beyond
Veranova has announced a major expansion of its Devens, Massachusetts facility, marking a significant step forward in the development and manufacturing of Antibody-Drug Conjugates (ADCs) and highly potent compounds. The company is investing $50 million to extend the facility by 9,000 square feet,
The biopharmaceutical industry finds itself at a crossroads as the ever-increasing global demand for pharmaceuticals necessitates a reevaluation of traditional manufacturing approaches. With escalating costs and inefficiencies hindering timely drug production, the sector is turning towards a
With the development of gene therapies in the treatment of genetic disorders, the recent advances made by CRISPR Therapeutics draw significant attention. The emergence of their flagship therapy, CASGEVY, presents a promising alternative, particularly for sickle cell disease. Sickle cell disease, a
In an era defined by environmental challenges and a greater emphasis on corporate responsibility, the biotech industry is at a crossroads where sustainability is not just a choice but an imperative. With an increasing number of companies committing to environmental, social, and governance (ESG)
In a groundbreaking move to push the boundaries of sustainable practices, the National Science Foundation has awarded $1.9 million to the Samueli School of Engineering at UCLA. This grant forms part of a larger $7.5 million initiative aimed at revolutionizing chemical manufacturing by employing
